Response seeks US OK for flu test:
This article was originally published in Clinica
Response Biomedical has filed a US 510(k) application to market its rapid, point-of-care test for influenza A and influenza B. The qualitative test will run on the the Vancouver, Canada-based firm's RAMP platform and will be marketed and sold exclusively by 3M Health Care as the 3M Rapid Detection Flu A+B Test. It uses as specimens nasal wash, nasal swab, nasopharyngeal aspirate and nasopharyngeal swab.
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.